Marc  Stapley net worth and biography

Marc Stapley Biography and Net Worth

Director of Glaukos
Mr. Stapley has served as a member of our Board of Directors since 2014. He is CEO and member of the board of directors of Veracyte Inc., a global diagnostics company he joined in June 2021. Prior to joining Veracyte, he served as CEO of Helix, a population genomics company, since April 2019. Prior to Helix, Mr. Stapley was the executive vice president, strategy and corporate development at Illumina, Inc., where he was responsible for corporate strategy, corporate and business development and global infrastructure, from 2017 to January 2019. Previously, Mr. Stapley served as Illumina’s chief administrative officer, senior vice president and chief financial officer. He was also a member of Illumina’s executive management team, which is responsible for directing all aspects of the company’s strategy, planning and operations. Before joining Illumina, from 2009 to 2012, Mr. Stapley was senior vice president, finance at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts in both the Wyeth Ltd. and King Pharmaceutical, Inc. acquisitions and providing oversight to the company’s largest technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas chief financial officer. He also worked as finance director and controller for several groups at Cadence Design Systems, Inc. He began his career as an Auditor at Coopers & Lybrand. He holds a B.Sc. (Honors) from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.

What is Marc Stapley's net worth?

The estimated net worth of Marc Stapley is at least $3.22 million as of February 29th, 2024. Mr. Stapley owns 32,360 shares of Glaukos stock worth more than $3,219,173 as of April 27th. This net worth evaluation does not reflect any other investments that Mr. Stapley may own. Learn More about Marc Stapley's net worth.

How do I contact Marc Stapley?

The corporate mailing address for Mr. Stapley and other Glaukos executives is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. Glaukos can also be reached via phone at (949) 367-9600 and via email at [email protected]. Learn More on Marc Stapley's contact information.

Has Marc Stapley been buying or selling shares of Glaukos?

Marc Stapley has not been actively trading shares of Glaukos within the last three months. Most recently, Marc Stapley sold 6,250 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $90.09, for a transaction totalling $563,062.50. Following the completion of the sale, the director now directly owns 32,360 shares of the company's stock, valued at $2,915,312.40. Learn More on Marc Stapley's trading history.

Who are Glaukos' active insiders?

Glaukos' insider roster includes Thomas Burns (CEO), Joseph Gilliam (CFO), Gilbert Kliman (Director), Marc Stapley (Director), and Alex Thurman (CFO). Learn More on Glaukos' active insiders.

Are insiders buying or selling shares of Glaukos?

During the last year, insiders at the medical instruments supplier sold shares 41 times. They sold a total of 725,957 shares worth more than $60,475,590.77. The most recent insider tranaction occured on April, 8th when CFO Alex R Thurman sold 1,372 shares worth more than $137,940.88. Insiders at Glaukos own 6.4% of the company. Learn More about insider trades at Glaukos.

Information on this page was last updated on 4/8/2024.

Marc Stapley Insider Trading History at Glaukos

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/29/2024Sell6,250$90.09$563,062.5032,360View SEC Filing Icon  
12/14/2023Sell16,250$75.93$1,233,862.5031,316View SEC Filing Icon  
See Full Table

Marc Stapley Buying and Selling Activity at Glaukos

This chart shows Marc Stapley's buying and selling at Glaukos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Glaukos Company Overview

Glaukos logo
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Read More

Today's Range

Now: $99.48
Low: $98.53
High: $100.60

50 Day Range

MA: $92.42
Low: $84.31
High: $101.19

2 Week Range

Now: $99.48
Low: $45.38
High: $103.66

Volume

288,895 shs

Average Volume

481,113 shs

Market Capitalization

$4.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08